Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ArriVent Biopharma
Biotech
ArriVent pays Lepu $47M for GI-focused preclinical ADC
A year after going public, ArriVent BioPharma is continuing to bolster its antibody-drug conjugate pipeline via licensing deals.
James Waldron
Jan 22, 2025 7:15am
ArriVent licenses ADC from $100M biobuck deal with Aarvik
Aug 15, 2024 8:58am
Alto aims for $101M IPO to pave neuro development climb
Jan 30, 2024 11:37am
IPO success stories suggest biotech has reached 'recovery phase'
Jan 26, 2024 10:21am
ArriVent brings in $175M for biotech’s second IPO of the year
Jan 26, 2024 5:14am
Arrivent unveils $135M IPO pricing to get furmonertinib to FDA
Jan 22, 2024 10:28am
